Airway diseases
E-poster
Inhaled treatments for COPD: clinical trials and real-world studies
Aims : This session is built from abstracts published on the ERS Congress platform from 23 August, in an e-poster pdf format with a 3-minute audio narration. Participants and chairs of the session are invited to access all e-posters from 23 August to 4 September prior to the 1-hour live, online discussion scheduled from September 5-7. Please note that during live discussion there will be NO e-poster/abstract presentations, only discussion.
Methods :
Public health, Pulmonary function testing, Epidemiology, General respiratory patient care
Relationship between baseline rescue medication use and reductions in COPD exacerbation rates: a subgroup analysis of the ETHOS trial
J. Hurst(London, United Kingdom)
COI
Benefits of triple therapy in moderate, severe, and very severe COPD: subgroup analysis of the ETHOS trial
K. Rabe(Kiel, Germany)
COI
Risk factors for all-cause mortality in patients with COPD: results from the ETHOS trial
G. Ferguson(Farmington Hills, United States)
COI
The association between health-related quality of life and COPD exacerbations measured by EQ-5D-5L in the ETHOS trial
D. Jackson(Cambridge, United Kingdom)
COI
Predicting SGRQ score based on CAT score: post-hoc analysis of the IMPACT trial
Factors influencing LAMA addition to COPD patients receiving ICS/LABA in clinical practice-RETRIEVE study.
S. Tryfon(Thessaloniki, Greece)
COI
Lung function and reported dyspnea in Greek COPD patients under treatment with fluticasone/salmeterol FDC via Elpenhaler device with or without cardiovascular comorbidity - AEOLOS study.
M. Bertoli(Pikermi, Greece)
COI
Improvements in lung function with umeclidinium/vilanterol analysed by reversibility at screening: a post hoc analysis of the EMAX trial
L. Bjermer(Lund, Sweden)
COI
Inhaled corticosteroid use and its association with Pseudomonas aeruginosa infection in COPD
H. Shafiek(Alexandria, Egypt)
COI
Are COPD prescription patterns aligned with guidelines? a population-based study
T. Bahremand(Vancouver, Canada)
COI
Clinical and economic impact of inhaled corticosteroid withdrawal in Spanish COPD patients treated with triple therapy
V. Neches(Tres Cantos, Spain)
COI
. . .
